News Alert: Moderna to ask FDA to greenlight its coronavirus vaccine — a milestone that brings the U.S. closer to 2 vaccines before year’s end

Moderna's two-dose vaccine regimen was 94 percent effective at preventing illness in a 30,000-person clinical trial, the company said — a performance that exceeds expectations and is on par with the best childhood vaccines. Experts anticipate there will be enough doses to inoculate 20 million people this year between Moderna's vaccine and a second from Pfizer and the German firm BioNTech. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Sign up for alerts News Alert Nov. 30, 7:03 a.m. EST Moderna to ask FDA to greenlight its coronavirus vaccine — a milestone that brings the U.S. closer to 2 vaccines before year's end Moderna's two-dose vaccine regimen was 94 percent effective at preventing illness in a 30,000-person clinical trial, the company said — a performance that exceeds expectations and is on par with the best childhood vaccines. Experts anticipate there will be enough doses to inoculate 20 million people this year between Moderna's vaccine and a second from Pfizer and the German firm BioNTech. Read more   Advertisement

Manage my email newsletters and alerts | Unsubscribe | Privacy Policy | Help You received this email because you signed up for news alerts or because it is included in your subscription. ©2020 The Washington Post | 1301 K St NW, Washington DC 20071